Sage Therapeutics, Inc. (SAGE)
NASDAQ: SAGE · IEX Real-Time Price · USD
12.98
-0.27 (-2.04%)
At close: May 7, 2024, 4:00 PM
12.89
-0.09 (-0.69%)
After-hours: May 7, 2024, 5:25 PM EDT
Sage Therapeutics Stock Forecast
Stock Price Forecast
The 16 analysts with 12-month price forecasts for Sage Therapeutics stock have an average target of 19.56, with a low estimate of 14 and a high estimate of 28. The average target predicts an increase of 50.69% from the current stock price of 12.98.
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for SAGE stock from 17 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 1 | 1 |
| Buy | 2 | 2 | 2 | 3 | 2 | 2 |
| Hold | 14 | 14 | 13 | 13 | 13 | 13 |
| Sell | 0 | 0 | 0 | 0 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 16 | 16 | 15 | 16 | 17 | 17 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Buy Maintains $29 → $28 | Buy | Maintains | $29 → $28 | +115.72% | May 1, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Maintains $28 → $25 | Hold | Maintains | $28 → $25 | +92.60% | Apr 26, 2024 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $28 → $19 | Hold | Maintains | $28 → $19 | +46.38% | Apr 26, 2024 |
| RBC Capital | RBC Capital | Hold Maintains $26 → $15 | Hold | Maintains | $26 → $15 | +15.56% | Apr 26, 2024 |
| Truist Securities | Truist Securities | Hold Maintains $22 → $18 | Hold | Maintains | $22 → $18 | +38.67% | Apr 26, 2024 |
Financial Forecast
Revenue This Year
37.83M
from 86.46M
Decreased by -56.24%
Revenue Next Year
137.50M
from 37.83M
Increased by 263.48%
EPS This Year
-6.37
from -9.05
EPS Next Year
-4.77
from -6.37
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 89.0M | 555.2M | 1.1B | 1.8B | 2.7B |
| Avg | 37.8M | 137.5M | 330.5M | 432.6M | 658.2M |
| Low | 11.8M | 34.9M | 109.0M | 148.1M | 197.5M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 2.9% | 1,367.6% | 701.5% | 452.9% | 518.3% |
| Avg | -56.2% | 263.5% | 140.3% | 30.9% | 52.1% |
| Low | -86.3% | -7.9% | -20.7% | -55.2% | -54.4% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -3.52 | 2.69 | 11.60 | -0.83 | - |
| Avg | -6.37 | -4.77 | -3.20 | -3.67 | -2.08 |
| Low | -7.76 | -7.00 | -6.99 | -5.39 | -4.09 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.